Shapiro Capital Management LLC Has $99.83 Million Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Shapiro Capital Management LLC lessened its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 5.5% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 945,127 shares of the medical equipment provider’s stock after selling 55,133 shares during the quarter. Zimmer Biomet accounts for approximately 3.4% of Shapiro Capital Management LLC’s holdings, making the stock its 9th largest position. Shapiro Capital Management LLC’s holdings in Zimmer Biomet were worth $99,834,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of ZBH. CKW Financial Group raised its stake in Zimmer Biomet by 11.7% during the fourth quarter. CKW Financial Group now owns 955 shares of the medical equipment provider’s stock valued at $101,000 after purchasing an additional 100 shares in the last quarter. Romano Brothers AND Company grew its holdings in shares of Zimmer Biomet by 1.1% in the fourth quarter. Romano Brothers AND Company now owns 9,466 shares of the medical equipment provider’s stock worth $1,000,000 after purchasing an additional 102 shares during the last quarter. Dorsey & Whitney Trust CO LLC grew its holdings in shares of Zimmer Biomet by 2.3% in the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 4,594 shares of the medical equipment provider’s stock worth $485,000 after purchasing an additional 102 shares during the last quarter. M&T Bank Corp grew its holdings in shares of Zimmer Biomet by 0.4% in the fourth quarter. M&T Bank Corp now owns 26,827 shares of the medical equipment provider’s stock worth $2,834,000 after purchasing an additional 108 shares during the last quarter. Finally, MGO One Seven LLC grew its holdings in Zimmer Biomet by 5.1% during the 4th quarter. MGO One Seven LLC now owns 2,254 shares of the medical equipment provider’s stock worth $238,000 after acquiring an additional 110 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Insider Activity

In related news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the transaction, the senior vice president now owns 8,768 shares of the company’s stock, valued at approximately $915,379.20. This trade represents a 14.13% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.39% of the company’s stock.

Zimmer Biomet Price Performance

Shares of ZBH opened at $96.68 on Friday. The firm has a market capitalization of $19.13 billion, a price-to-earnings ratio of 21.73, a price-to-earnings-growth ratio of 1.95 and a beta of 0.78. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. Zimmer Biomet Holdings, Inc. has a one year low of $89.92 and a one year high of $122.17. The stock’s fifty day moving average is $103.62 and its 200-day moving average is $105.92.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, beating analysts’ consensus estimates of $1.77 by $0.04. The company had revenue of $1.91 billion for the quarter, compared to analyst estimates of $1.89 billion. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. The company’s quarterly revenue was up 1.1% compared to the same quarter last year. During the same period last year, the company earned $1.94 earnings per share. Equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st were issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.99%. The ex-dividend date of this dividend was Monday, March 31st. Zimmer Biomet’s dividend payout ratio (DPR) is 21.24%.

Wall Street Analyst Weigh In

Several research firms have commented on ZBH. JPMorgan Chase & Co. decreased their price target on shares of Zimmer Biomet from $128.00 to $105.00 and set an “overweight” rating for the company in a research report on Tuesday, May 6th. Morgan Stanley decreased their price objective on shares of Zimmer Biomet from $115.00 to $95.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 6th. BTIG Research reaffirmed a “buy” rating on shares of Zimmer Biomet in a research report on Monday, April 14th. Robert W. Baird decreased their price objective on shares of Zimmer Biomet from $130.00 to $115.00 and set an “outperform” rating for the company in a research report on Tuesday, May 6th. Finally, Wells Fargo & Company decreased their price objective on shares of Zimmer Biomet from $113.00 to $98.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 6th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, Zimmer Biomet currently has an average rating of “Hold” and a consensus price target of $113.45.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.